Jefferies analyst Chris Howerton raised the price target on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

BioXcel Therapeutics (BTAI) PT Raised to $84 at Canaccord GenuityApril 7, 2022 7:56 AM BioXcel Therapeutics (BTAI) PT Raised to $80 at BofA SecuritiesApril 6, 2022 11:09 AM Pre-Open Stock Movers 04/06: (TUFN) (BTAI) (TLRY) Higher; (CANO) (CAR) (JBLU) Lower (more...)April 6, 2022 9:02 AM BioXcel Therapeutics (BTAI) Announces FDA Approval of IGALMI Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in AdultsApril 6, 2022 7:00 AM BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in AdultsApril 6, 2022 7:00 AM BioXcel Therapeutics (BTAI) Halted, News PendingApril 6, 2022 6:56 AM Form DEFA14A BioXcel Therapeutics, April 5, 2022 8:30 AM Form DEF 14A BioXcel Therapeutics, For: May 19April 5, 2022 8:29 AM